PTK2 and hepatocellular carcinoma: These results are supported by previous studies demonstrating sunitinib in combination with PF-562,271, another small molecule FAK inhibitor, had a greater anti-tumor effect with decreased tumor volume and increased tumor necrosis compared to monotherapy for human hepatocellular carcinoma in a rat xenograft model [59].